Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells

被引:21
|
作者
deFabritiis, P
Skorski, T
DePropris, MS
Paggi, MG
NieborowskaSkorska, M
Lisci, A
Buffolino, S
Campbell, K
Geiser, T
Calabretta, B
机构
[1] REGINA ELENA INST CANC RES,I-00161 ROME,ITALY
[2] THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,PHILADELPHIA,PA 19107
[3] LYNX THERAPEUT,HAYWARD,CA
关键词
bcr-abl oligonucleotides; p210(bcr-abl); chronic myelogenous leukaemia; CD34(+) cells;
D O I
10.1038/sj.leu.2400664
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We studied the effect of phosphorothioate oligodeoxynucleotides ([S]ODNs) complementary to the bcr-abl junction on cells taken at diagnosis from 41 patients with Philadelphia-positive chronic myelogenous leukaemia (CML). Experiments included the evaluation of the anti-leukaemic effect of 16- and 26-mer antisense [S]ODNs on both mononuclear and CD34(+) cells, evaluation of incubation time and correlation of colony growth inhibition with the down-regulation of p210(bcr-abl). At the same time, the uptake of [S]ODNs by mononuclear and purified CD34(+) cell populations and the cross-hybridization of 26- and 16-mer [S]ODNs with the complementary sequences were evaluated. After incubation for 120 h with 26-mer antisense [S]ODNs on mononuclear cells, overall mean colony recovery was 41.9% of the untreated control samples; in particular, a significant reduction in colony formation was observed in 22 of the 35 cases tested. The effect of 26-mer ODNs on CD34(+) cells was comparable to that observed on mononuclear cells in terms of colony inhibition; however, a higher proportion of cases showed a significant inhibition of colony formation. In comparison with the 26-mer antisense [S]ODNs, the anti-leukaemic effect of the 16-mer antisense [S]ODNs was less evident on mononuclear cells and comparable on CD34(+) cells; however, a more specific effect was evident on both target cells. Hybridization experiments confirmed a partial cross-reactivity when the 26-mer ODNs were hybridized with their complementary sequence; this did not occur when 16-mer ODNs were similarly tested. Experiments aimed at evaluating the effect of the incubation time showed a significant increase in anti-leukaemic effect after a 120 h incubation period compared to that measured after a 24 h incubation period; this was parallelled by a progressive increase in the intracellular concentrations of [S]ODNs from day 1 to day 5. The accumulation of [S]ODNs correlated with a marked down-regulation of p210(bcr-abl) levels which was first detectable after 72 h of treatment. The downregulation of p210(bcr-abl) levels following treatment with [S]ODNs showed a correlation between the effect of antisense [S]ODNs on leukaemic colony formation and protein expression. These studies confirm that, under optimal conditions of target cell culture and ODN size, antisense [S]ODNs complementary to the bcr-abl junction have specific anti-leukaemic effects.
引用
收藏
页码:811 / 819
页数:9
相关论文
共 50 条
  • [31] CCN3 expression reduces the clonogenic potential and growth of BCR-ABL plus cells
    Mccallum, LMR
    Lu, W
    Price, S
    Planque, N
    Perbal, B
    Pierce, A
    Whetton, AD
    Irvine, AE
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 13 - 14
  • [32] Improved efficiency of growth inhibition of BCR-ABL positive cells by antisense oligodeoxynucleotides-cholesterol.
    Faber, E
    Andrews, DF
    Shadduck, RK
    Geyer, S
    Agha, ME
    BLOOD, 1995, 86 (10) : 3977 - 3977
  • [33] RAS IS ESSENTIAL FOR TRANSFORMATION BY THE BCR-ABL ONCOGENE OF CHRONIC MYELOGENOUS LEUKEMIA
    SAWYERS, CL
    MCLAUGHLIN, J
    HAVLIK, M
    WITTE, O
    BLOOD, 1993, 82 (10) : A331 - A331
  • [34] BCR-ABL - AN ANTI-APOPTOSIS GENE IN CHRONIC MYELOGENOUS LEUKEMIA
    COTTER, TG
    LEUKEMIA & LYMPHOMA, 1995, 18 (3-4) : 231 - 236
  • [35] Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia
    O'Dwyer, ME
    Druker, BJ
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (06) : 594 - 597
  • [36] Mechanism of stability and degradation of the chronic myelogenous leukemia oncoprotein, BCR-ABL
    Tsukahara, F
    Maru, Y
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 105P - 105P
  • [37] Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation
    Roman, J
    Parziale, A
    Gottardi, E
    De Micheli, D
    Cilloni, D
    Tiribelli, M
    Gonzalez, MG
    Rodriguez, MD
    Torres, A
    Saglio, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (02) : 644 - 646
  • [38] Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more
    Cea, M.
    Cagnetta, A.
    Garuti, A.
    Cirmena, G.
    Rocco, I.
    Moran, E.
    Grillo, V.
    Ballestrero, A.
    Patrone, F.
    Nencioni, A.
    JOURNAL OF BUON, 2009, 14 (04): : 565 - 573
  • [39] A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic myelogenous leukaemia
    Okamoto, K
    Karasawa, M
    Sakai, H
    Ogura, H
    Morita, K
    Naruse, T
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (03) : 611 - 613
  • [40] ALTERNATIVE 5' END OF THE BCR-ABL TRANSCRIPT IN CHRONIC MYELOGENOUS LEUKEMIA
    ROMERO, P
    BERAN, M
    SHTALRID, M
    ANDERSSON, B
    TALPAZ, M
    BLICK, M
    ONCOGENE, 1989, 4 (01) : 93 - 98